Randomized, Double-blind Trial Evaluating the Safety and Efficacy of a 21-day Course of Albendazole 400mg/Day in Subjects With High Loa Loa Microfilaremia

Our aim is to test the hypothesis that a 3-week course of albendazole 400 mg daily is safe and can progressively reduce Loa loa microfilarial densities in subjects with microfilaremia.

Start Date15 Jan 2025

Sponsor / Collaborator

Institut de Recherche pour le Développement

CTRI/2024/07/070861 / Not yet recruitingPhase 2/3IIT

A comparative clinical trial to study the effect of Triphaladi ghrita and albendazole in the management of Krimi roga in children. - NIL

Start Date15 Aug 2024

Sponsor / Collaborator-

NCT06497075 / Active, not recruitingNot ApplicableIIT

The Feasibility and Acceptability of the Co-administration of Ivermectin and Albendazole Vs Albendazole Alone, in the Frame of Mass Drug Administration to School-aged Children in Uganda: a Small-scale Implementation Pilot Study

The goal of this small-scale implementation research pilot study is to assess the feasibility and acceptability of the co-administration of ivermectin (IVM) and albendazole (ALB) compared to albendazole alone during school-based mass drug administration in Uganda. The study will target up to 10,000 school-aged children from 20 schools in Kabale and Kisoro districts in South-Western Uganda.
The main questions it aims to answer are:
* How feasible is the introduction of co-administered IVM plus ALB in the routine school-based deworming campaign in terms of training, material and processes?
* How well do beneficiary communities (pupils, parents) and implementers (teachers, health workers) accept the new treatment scheme and what are potential barriers and enablers for uptake?
* What are common implementation-related costs that can inform the methodology to estimate monetary and non-monetary costs as well as performance of the two treatment arms for the future cost-effectiveness analysis?
The study employs a cross-sectional mixed-method design (we will collect qualitative and quantitative data) to evaluate the feasibility and acceptability of co-administering IVM and ALB versus ALB alone in routine school-based mass drug administration. Assessments will take place during and after the drug distribution to document the implementation process and evaluate experiences made by the different stakeholders (e.g. children, parents, teachers, health workers):
* The implementation activities start with a training of all implementers at district level who will also undergo a pre- and post-training knowledge assessment.
* Schoolchildren aged 5-14 years will receive a single dose of ALB alone or co-administered ALb (400mg) and IVM (200µg/kg; as determined by height category on a dose pole) by health workers at school. 1-2 weeks post-distribution a subsample of 19 children per school will be invited to answer to questionnaires administered by social science researchers.
* Implementers will administer the treatments and document all distribution-related aspects during the campaign under supervision of the routine staff. Researchers will conduct additional monitoring and evaluation in order to assure data quality and provide support in performance assessment and cost evaluation.
* Beneficiaries (parents) and implementers will be asked to take part in focus group discussions and questionnaire interviews one week after the drug distribution.

Start Date01 Jul 2024

Sponsor / Collaborator

Swiss Tropical & Public Health Institute

[+1]

100 Clinical Results associated with Albendazole

100 Translational Medicine associated with Albendazole

100 Patents (Medical) associated with Albendazole

6,130

Literatures (Medical) associated with Albendazole

01 Jan 2025·Colloids and Surfaces B: Biointerfaces

Albendazole nanosuspension coated granules for the rapid localized release and treatment of colorectal cancer

Article

Author: Patel, Henis J ; Patel, Akanksha S ; Squillante, Emilio ; Guo, Yi ; Patel, Ketan

Albendazole (ABZ), an anthelmintic drug, has been repurposed to treat various types of cancers. However, poor solubility of ABZ, resulting in low bioavailability, limits its application. Nanosuspension is a versatile method for enhancing the dissolution of hydrophobic molecules, but a successful drying has been the biggest challenge in the field. The objective of this research is to formulate and optimize ABZ nanosuspension (NS) coated granules for rapid delivery of ABZ for the treatment of colorectal cancer. ABZ NS was prepared by dual centrifugation method using Kollidon® VA64 and sodium lauryl sulphate (SLS) as stabilizers. The processing method was optimized to obtain a stable nanosuspension with particle size < 300 nm. The optimized ABZ NS was coated on microcrystalline cellulose (MCC) to form the nano-coated granules (NCG) and filled in EUDRACAP® for colon targeted delivery. The ABZ NS and NCG achieved ∼ 60 % and ∼55 % drug release, respectively, in presence of bile salt at colonic pH. Half-maximal inhibitory concentration (IC₅₀) of ABZ NS was found to be 1.18 ± 0.081 µM and 3.59 ± 0.080 µM in two colorectal cancer cell lines: HCT 116 and HT-29, respectively. In addition, In vitro 3D tumor assay revealed that ABZ NS has superior tumor growth inhibition activity compared to the control and pure ABZ. The preparation of ABZ NCG in EUDRACAP® could be a promising approach to achieve colon targeted delivery and to repurpose ABZ for the treatment of colorectal cancer.

06 Dec 2024·Journal of Biomolecular Structure and Dynamics

Network pharmacology and molecular docking study-based approach to explore mechanism of benzimidazole-based anthelmintics for the treatment of lung cancer

Article

Author: Nidhi ; Khan, Imran A. ; Khan, Mohd Ashif ; Reeta ; Garg, Aakriti ; Karhana, Sonali ; Bano, Aysha

Emerging studies have reported the potential anticancer activity of benzimidazole-based anthelmintics (BBA) against lung cancer (LC). However, mechanism underlying the anticancer activity of BBA is unclear. Therefore, in the current study, network pharmacology and molecular docking-based approach were used to explore the potential molecular mechanism for the treatment of LC. The potential targets for BBA were obtained from multiple databases including SwissTargetPrediction, Drug Bank, Therapeutic Target Database, and Comparative Toxicogenomics Database while LC targets were collected from DisGeNet gene discovery platform, Integrated Genomic Database of NSCLC, Catalogue of Somatic Mutations in Cancer and Online Mendelian Inheritance in Man database. Protein-protein interaction (PPI) diagram of common targets was constructed using STRING online platform. Topological analysis was performed using Cytoscape and gene enrichment analysis was conducted using FunRich software. Highest degree targets were then confirmed using molecular docking and molecular dynamics simulations. The BBA were prioritized according to their S scores, with ricobendazole ranking highest followed by flubendazole, fenbendazole, mebendazole, triclabendazole, albendazole, oxibendazole, parbendazole, thiabendazole and oxfendazole. The potential targets of BBA identified using topological analysis and molecular docking were found to be CCND1 (cyclin D1), EGFR (Epidermal Growth Factor Receptor), ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2/CD340), PTGS2 (Prostaglandin-endoperoxide synthase 2), and SRC (Proto-oncogene tyrosine-protein kinase). Furthermore, molecular dynamics confirmed that CCND1 and EGFR are the potential targets of ricobendazole for the treatment of LC. BBA can be further explored as a therapeutic strategy for the treatment of lung cancer under in vitro and in vivo studies.Communicated by Ramaswamy H. Sarma.

01 Dec 2024·Parasitology International

Sustainable approach to control gastrointestinal nematodes using pelargonium quercetorum Agnew in goats

Article

Author: Ghaderi, Hiva ; Rokhzad, Babak ; Mohammadian, Baharak ; Mafakheri, Shiva ; Bahmani, Hamid Reza

The use of medicinal plants as a means of combating parasites is becoming increasingly popular due to general resistance to synthetic anthelmintics. Goats typically respond less well to anthelminthic treatments, which may increase their resistance to nematodes. For this purpose, the anthelmintic effect of Pelargonium quercetorum Agnew (P. quercetorum) extract was tested in an in vivo study against gastrointestinal parasites of goats. A total of 40 goats naturally infected with mixed gastrointestinal nematode species were divided into four groups: the first group was treated with albendazole (7.5 mg/kg), the second group received a single dose of closantel (7.5 mg/kg), the third group received plant extract (7.5 mg/kg), and the fourth group served as an untreated control. Fecal egg counts (FEC) were carried out on day 14, as well as day 0, which was prior to the first treatment dose. According to the results, maximum reduction in FEC percentage was observed in P. quercetorum treated group (63.41%). Furthermore, nematode parasites responded poorly to synthetic drugs, although there was a 4.72% and 45.54% decrease in FEC in the albendazole and closantel-treated groups, respectively. Although no significant difference was found between the treatment groups, the P. quercetorum treated group showed a significant reduction in fecal egg count after treatment. Based on findings, a P. quercetorum based anthelmintic could be a sustainable alternative to combat parasite infestation. Therefore, further studies are needed to determine the optimal dose rate and frequency of doses required for effective control of gastrointestinal parasites in goats.

News (Medical) associated with Albendazole

12 Nov 2024

·www.globenewswire.com

Timor-Leste eliminates lymphatic filariasis as a public health problem

DECATUR, Ga., Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Mectizan Donation Program applauds Timor-Leste for eliminating lymphatic filariasis (LF) as a public health problem, a remarkable achievement that was recently validated by the World Health Organization (WHO). Timor-Leste is the fifth country in Southeast Asia to achieve this milestone and the first country in the region to do so by co-administering Mectizan, albendazole and diethylcarbamazine (DEC). Since 2017, Merck (known as MSD outside of the U.S. and Canada), GSK and Eisai have been partnering to donate Mectizan, albendazole, and DEC, respectively, to accelerate the elimination of LF in eligible countries where river blindness is not endemic based on a recommendation of triple drug therapy from WHO. LF, commonly known as elephantiasis, is a debilitating disease caused by a parasite transmitted by mosquitoes. Long-term, chronic infection can cause damage to the lymphatic system, as well as severe and irreversible swelling to the limbs, breasts and/or genitals. These symptoms can cause extreme discomfort, disability and social stigmatization. “We are delighted to learn of Timor-Leste’s success in eliminating LF as a public health problem,” said Allison Goldberg, president, Merck Foundation. “This achievement is a testament to the strength and determination of the Timor-Leste people and the power of public-private partnerships, including the Mectizan Donation Program.”Thomas Breuer, Chief Global Health Officer at GSK, stated, “We congratulate Timor-Leste for this remarkable achievement. The elimination of lymphatic filariasis as a public health problem in Timor-Leste is demonstrative of the power of effective partnerships and the unwavering commitment of the global NTD community.” Mectizan Donation Program director Dr. Yao Sodahlon, an expert in tropical diseases who played a vital role in the elimination of LF in Togo, stated, “We celebrate the government of Timor-Leste, the endemic communities who helped distribute the medicines with high coverage demonstrating effectiveness of triple drug therapy, and the partners who made elimination of LF in Timor-Leste possible. This success demonstrates that elimination of LF can be achieved through the donations of these essential medicines, the commitment of the government and people of the endemic countries, and the global partnership working to end LF.” About the Mectizan Donation Program The Mectizan Donation Program (MDP) was established in 1987 to provide medical, technical, and administrative oversight of the donation of Mectizan by Merck for the treatment of onchocerciasis, also known as river blindness. In 1998, MDP expanded its mandate to include oversight of the donation of albendazole by GSK for the elimination of lymphatic filariasis in onchocerciasis co-endemic areas. Contacts MDP:Joni Lawrence Deputy Director Mectizan Donation Program jlawrence@taskforce.org Yao SodahlonDirectorMectizan Donation Programysodahlon@taskforce.org

18 Oct 2023

·www.prnewswire.com

Lao PDR Reaches Incredible Milestone in Mitigating Neglected Tropical Diseases with Elimination of Lymphatic Filariasis

RTI International congratulates Lao PDR in eliminating LF — a disabling disease impacting the lives of millions of people around the world RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2023 /PRNewswire/ -- RTI International, a nonprofit research institute and leading international development organization, joins the Lao People's Democratic Republic (Lao PDR), World Health Organization, and the U.S. Agency for International Development (USAID) in celebrating Lao PDR's achievement of eliminating lymphatic filariasis as a public health problem. Also known as elephantiasis, lymphatic filariasis is a neglected tropical disease (NTD) that can cause swollen extremities in a person and lead to severe disfigurement and disability, as well as social and economic discrimination against those affected. As of the latest data released by WHO last week, more than 793 million people required treatment for this disease across 44 countries in Asia, Africa, the Western Pacific, and parts of the Caribbean and South America. WHO officially confirmed this week that the people of Lao PDR are no longer at risk of contracting the disease. "RTI sends our sincerest congratulations to the government of Lao PDR and its people for solving this pressing public health problem," said Tim Gabel, president and CEO of RTI International. "It is particularly significant given that Lao PDR achieved the elimination of trachoma as public health problem in 2017, demonstrating the power of national commitment to ending neglected tropical diseases." RTI supported this milestone through its leadership of USAID's Act to End NTDs | East program, which has advanced the sustainable control and elimination of NTDs in 13 countries across Africa, Asia and Latin America. RTI worked with the government of Lao PDR to compile the data and information needed to establish proof that the country had eliminated lymphatic filariasis as a public health problem. Additionally, with USAID support, RTI assisted the government to develop a plan to monitor and track progress against the disease to ensure elimination is sustained in the future. "Lao PDR is the latest example of a country that worked hard to go the last mile to reach lymphatic filariasis elimination and free its people from this disabling disease," said  Lisa Rotondo, Director of USAID's Act to End NTDs | East program at RTI. "Global momentum towards eliminating lymphatic filariasis as a public health problem, led by countries themselves, is only growing. We are proud to be among the partners that supported the Lao PDR Ministry of Health to achieve this important milestone for its people." The elimination of lymphatic filariasis in Lao PDR was supported by many partners including USAID, RTI, FHI360, WHO, Mac Foundation, and the Asian Development Bank. In addition, albendazole treatments were donated by GlaxoSmithKline through the WHO donation program for NTD medicines. The Southeast Asian country now becomes the 19th country to have achieved validation of lymphatic filariasis elimination, marking another important public health milestone for the country and globally. Recently, Bangladesh also eliminated lymphatic filariasis with support from the Act to End NTDs | East program, led by RTI. Learn more about RTI's work to control and eliminate NTDs around the globe Media Contact: Kerry Branon 919 708-8205 [email protected] SOURCE RTI International

16 Jun 2023

·www.prnewswire.com

ANTECH DIAGNOSTICS PRESENTS LARGEST MOLECULAR STUDY ON GI PARASITES IN PETS AT ACVIM, SHARING NEW INSIGHTS ON PREVALENCE IN NORTH AMERICA

Results data drawn from a subset of samples tested in KeyScreen® GI Parasite PCR's first 10 months shows widespread problem with parasites in dogs and cats FOUNTAIN VALLEY, Calif., June 16, 2023 /PRNewswire/ -- Antech Diagnostics presented its largest molecular parasite study1 to date at the American College of Veterinary Internal Medicine's (ACVIM) Forum 2023. The first research abstract of two presented by Antech this year, studied a large subset of fecal samples - over 300,000 - from cats and dogs amassed in the first 10 months following KeyScreen® GI Parasite PCR's 2022 launch. As reported in the study1, molecular diagnostic testing revealed over a quarter of dogs and cats from the studied population were infected with parasites (1 in 4), which shows much more sensitive detection than conventional fecal testing (1 in 10). KeyScreen is the most advanced and comprehensive molecular diagnostic test, which can quickly detect 20 intestinal parasites in cats and dogs from a single 0.15 gram fecal sample, including markers for zoonotic Giardia and drug-resistant hookworm. Evidence showed 1 in 4 dogs and cats (over 25%) were infected with at least one parasite, and co-infections (two or more parasites found in a single fecal sample) were detected in 1 in 5 pets with parasites (over 20%). Among the dog samples that identified hookworm, 1 in 10 (over 11%) were found to have the marker for anthelmintic drug (benzimidazole)-resistance.1 In addition to uncovering a much higher frequency of parasite infection, further research also shows the parasite problem to be more widespread in North America– both geographically and across dog breeds - than previously believed. Research supports a growing body of KeyScreen data Another KeyScreen study into anthelmintic-resistant canine hookworms in North America had found that the problem is much more widespread across the US. 2 This new data shows that in North America, over 11% of detected canine hookworms were identified with the drug resistance marker 167Y. 1 In addition, the problem of hookworm resistance is now emerging in Canada. Treatment resistance hookworm markers have been found in more than 72 dog breeds, indicating that this is no longer just a problem in greyhounds. Drug-resistant hookworms are a problem North American veterinarians need to be aware of.3 Second ACVIM presentation highlights new drug resistance marker A second KeyScreen research study presented at ACVIM today, highlights how these drug-resistant parasites are rapidly adapting, through investigation of another recently discovered hookworm benzimidazole treatment resistance marker. 3,4 This new marker (134H) increased the detection of hookworm benzimidazole treatment resistance by 25% in dog hookworm detected samples (143) collected in Florida. The existing drug resistance marker 167Y was found in 31 samples, while the marker 134H was found in an additional 8, thereby increasing the rate of resistant strains by 25%. Because of Antech's agility, as of June 1, 2023, this second marker is now included in KeyScreen, providing additional practical – and the most advanced - information for veterinarians. KeyScreen's real-world impact KeyScreen is revolutionizing the field of routine veterinary parasite screening, by providing more detailed information on how parasites are adapting, emerging and spreading geographically. It is also highlighting One Health (the interconnection between human, animal and environmental health led by WHO, and in the US by the CDC) and pharmacological stewardship. In practice, KeyScreen is part of veterinary day-to-day routine wellness, and in line with evidence and expert-based recommendations from CAPC/CPEP, which helps create the most accurate parasite profile possible for every pet. And by doing so, veterinarians can provide the most efficient and effective care to protect the health of pets, their families and the broader community. Dr. Christian M. Leutenegger, Vice President of research and development at Antech and KeyScreen inventor who presented both abstracts at ACVIM Forum 2023 said: "Until recently, parasites have been adapting at a rate that has outpaced technology. KeyScreen is a significant advancement in veterinary diagnostics, providing a powerful tool to detect parasites in a way we have never been able to before. This innovation has important implications for GI parasite One Health and also, antimicrobial stewardship. DNA doesn't lie, it's either there or it's not – there is no subjectivity." Find out more about KeyScreen here: About KeyScreen KeyScreen™ GI Parasite PCR is the most comprehensive GI parasite screening solution for cats and dogs. It uses molecular technology (PCR) to quickly detect and amplify small segments of nuclei acid from parasites' DNA or RNA, providing actionable insights that enable veterinarians to better care for pets, protect people and the environment, and practice antimicrobial stewardship to help preserve parasiticides. KeyScreen can detect 20 intestinal parasites from a single, storable 0.15 gram fecal sample. It can uniquely detect markers for anthelmintic drug-resistant hookworm and potentially zoonotic Giardia in addition to co-infections, all of which influence treatment selection, helping veterinarians uphold pharmacological stewardship and One Health principles. KeyScreen delivers a full report, along with other core diagnostic results, in just 24-48 hours, saving you time in clinic and providing a level of precision that's impossible to achieve with traditional O&P and ELISA methods. By making advanced molecular parasite screening practical for routine wellness exams, KeyScreen provides veterinarians with a faster, more accurate path to positively impact the health of pets, people, and the broader community. About Antech At the heart of Antech is our love for pets and our desire to see them live longer, healthier lives. Through superior diagnostic testing delivered with a flexible, can-do spirit, we endeavor to treat every sample as if it belongs to our own pet. Our innovative diagnostics, accessible through North America's largest reference laboratory network, span world-class imaging equipment, and services, advanced molecular and predictive diagnostic testing, and core diagnostics with gold-standard accuracy. 24x7 access to the most accomplished team of board-certified pathologists, medical consultants across 14 specialty areas, and industry-leading education round out our support for today's high-performance practices. Antech is helping to drive the future of veterinary care as part of Mars Petcare, a purpose-driven global business serving pets and pet owners through products and services within veterinary health and diagnostics, nutrition, innovation, and technology. Visit us at antechdiagnostics.com. Follow us on Instagram, Twitter, LinkedIn, and Facebook. References Christian M Leutenegger, et al. Frequency of intestinal parasites in dogs and cats identified by molecular diagnostics. ACVIM abstract 2023. Christian M Leutenegger, et al. Emergence of Acylostoma caninum parasites with the F167Y polymorphism in the US dog population. 2023. Int, J. Parasitol. Drugs Drug Resist. 21, 131-140. Christian M Leutenegger, et al. Associated of the novel benzimidazole resistance marker Q134H with F167Y in dogs with Ancylostoma caninum. ACVIM abstract 2023. Abhinaya Venkatesan, et al. Molecular evidence of widespread benzimidazole drug resistance in Ancylostoma caninum from domestic dogs throughout the USA and discovery of a novel β-tubulin benzimidazole resistance mutation. 2023. PLoS Pathog. Mar 2;19(3):e1011146. Logo - SOURCE Antech Diagnostics

Clinical StudyClinical Result

100 Deals associated with Albendazole

External Link

KEGG	Wiki	ATC	Drug Bank
D00134	Albendazole	P02CA03	DB00518

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cystitis	JP	GlaxoSmithKline KK	19 Jan 1994
Helminthiasis	CN	Hubei Huazhong Pharmaceutical Co. Ltd.	01 Jan 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Intestinal Diseases	Phase 1	IN	GSK Plc	21 Aug 2023
Helminthiasis	Phase 1	CN	GSK Plc	01 Apr 2012
HIV Infections	Phase 1	US	Smithkline Beecham	31 Aug 2001
Microsporidiosis	Phase 1	US	Smithkline Beecham	31 Aug 2001
Protozoan Infections	Phase 1	US	Smithkline Beecham	31 Aug 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04326868 (Pubmed)	Phase 4	Infectious Diseases	-	Albendazole 400 mg	(pgmucxzlxo) = hubnrupnte mqejmlgrgz (wvzgptwcif, 58 - 81) View more	-	02 Apr 2024
NCT03527732 (CTgov)	Phase 2/3	Trichuriasis	1,673	Albendazole (Albendazole in Côte d'Ivoire)	xrvxsozrqb(bimfmimnoq) = gwnmhzkojv obzrfkadov (tsobcqrypr, otvjnjajwu - ronfxubodj) View more	-	20 Mar 2024
				Albendazole+Ivermectin (Albendazole and Ivermectin in Côte d'Ivoire)	xrvxsozrqb(bimfmimnoq) = ztoandzthj obzrfkadov (tsobcqrypr, jkfsurxhrs - zvcmfdofab) View more
NCT04410406 (Pubmed \| PLoS Negl Trop Dis)	Phase 3	Elephantiasis, Filarial Wuchereria bancrofti microfilaremia	-	ivermectin + albendazole	(ejsgagfrnt) = Four participants had transient Grade 3 hematuria after treatment (3 after IDA and 1 after IA) kusmohbcja (hpknkanect ) View more	Positive	18 Sep 2023
				moxidectin + albendazole
PACTR202202738940158 (Pubmed)	Not Applicable	Hookworm Infections	225	Dual-dose albendazole	wjrsebodqa(jcifcqzufs) = zjfavpubjk oileejxpij (oiwdsbjqoz, 90.9 - 99) View more	-	01 Jul 2023
				Single-dose albendazole	wjrsebodqa(jcifcqzufs) = zqzafisrkl oileejxpij (oiwdsbjqoz, 75.7 - 90.2) View more
NCT04188301 (DOLF IDA/Oncho, CTgov)	Phase 2	Onchocerciasis	154	Albendazole+Ivermectin (IVM + ALB)	qeyaxqkytx(svzeluogfs) = rcccbjfdlh adncxzxocs (avcwehpwun, xtswmdqvlb - ruquwvbbmc) View more	-	10 May 2023
				albendazole+ivermectin+diethylcarbamazine (IDA x 1 Dose)	qeyaxqkytx(svzeluogfs) = vsrkvgwbvw adncxzxocs (avcwehpwun, mfmackxtyg - xiiqjjqeck) View more
NCT04726969 (CTgov)	Phase 3	Trichuriasis \| Ascariasis \| Hookworm Infections	255	Albendazole 400 mg Oral Tablet+Moxidectin 2 mg Oral Tablet (Arm A: Moxidectin and Albendazole)	vqkrsppqwh(ghjbqquitp) = zeknjfxkra lcquciepmo (kpiuzrsdjr, uzifuuxmxa - qihpkdlpbm) View more	-	02 Feb 2023
				Albendazole 400 mg Oral Tablet (Arm B: Albendazole)	vqkrsppqwh(ghjbqquitp) = xvjrttbxjp lcquciepmo (kpiuzrsdjr, kjxplnzrtg - fqeyhctmve) View more
EAN	Not Applicable	Encephalomyelitis	-	Levamisole	zvrshdomkr(vmdjoleybm) = gbavfavyfh kcndwrzzma (gxothovsrw )	-	24 Jun 2022
				Albendazole	zvrshdomkr(vmdjoleybm) = jkxvvjohlb kcndwrzzma (gxothovsrw )
NCT02899936 (Pubmed \| PLoS Negl Trop Dis)	Not Applicable	Elephantiasis, Filarial	23,789	Albendazole + Diethylcarbamazine + Ivermectin	(adokaafykh) = The overall frequency of AEs were similar after either DA (18%) or IDA (20%) treatment wenqhkgzty (sohhpojfph ) View more	Positive	09 Feb 2022
				Diethylcarbamazine + Albendazole
NCT03527732 (Pubmed)	Phase 2/3	Helminthiasis	1,673	Ivermectin-albendazoleIvermectin-albendazole	(zoverzwjuf) = sulduhabpd uioqoywhkf (kbwvjwyzsx ) View more	-	30 Jun 2021
				Albendazole	(zoverzwjuf) = fsnazyduzn uioqoywhkf (kbwvjwyzsx ) View more
NCT02899936 (Pubmed \| PLoS Negl Trop Dis)	Not Applicable	Filariasis	23,789	Ivermectin plus diethylcarbamazineIvermectin plus diethylcarbamazine and albendazole	ygtnpepuml(urorojxklo) = About 45% of persons in both treatment groups experienced AE such as fever, muscle aches, lower back, joint and abdominal pain. These were mostly mild and most common during the first two days after treatment. No participant experienced a severe or serious AE. lpfzwviums (rivwfxjbfd )	-	29 Mar 2021
				Diethylcarbamazine plus albendazole

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis